Lakefront Biotherapeutics Completes Sale Of Early-Stage Cell Therapy Pipeline To Armed Cell Therapeutics For €8M Upfront, Up To $230M In Milestones

Loading news article.

Lakefront Biotherapeutics Completes Sale Of Early-Stage Cell Therapy Pipeline To Armed Cell Therapeutics For €8M Upfront, Up To $230M In Milestones | WAPE

Lakefront Biotherapeutics Completes Sale Of Early-Stage Cell Therapy Pipeline To Armed Cell Therapeutics For €8M Upfront, Up To $230M In Milestones

Article summary

Related companies

Comments —